

Lorenzo Leggio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1093539/publications.pdf>

Version: 2024-02-01

218
papers

9,774
citations

29994

54
h-index

51492

86
g-index

224
all docs

224
docs citations

224
times ranked

8083
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol use disorder in community management of chronic liver diseases. <i>Hepatology</i> , 2023, 77, 1006-1021.	3.6	13
2	A closer look at alcohol-induced changes in the ghrelin system: novel insights from preclinical and clinical data. <i>Addiction Biology</i> , 2022, 27, e13033.	1.4	17
3	Anabolic androgenic steroids used as performance and image enhancing drugs in professional and amateur athletes: Toxicological and psychopathological findings. <i>Human Psychopharmacology</i> , 2022, 37, e2815.	0.7	11
4	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 45-59.	8.2	50
5	Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 519-541.	2.9	1
6	Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 186-195.	3.7	28
7	From "Hunger Hormone" to "It's Complicated": Ghrelin Beyond Feeding Control. <i>Physiology</i> , 2022, 37, 5-15.	1.6	19
8	Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. <i>Pharmacological Reviews</i> , 2022, 74, 119-140.	7.1	72
9	Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. <i>Molecular Psychiatry</i> , 2022, 27, 2171-2181.	4.1	9
10	Involvement of the ghrelin system in the maintenance and reinstatement of cocaine-motivated behaviors: a role of adrenergic action at peripheral β_1 receptors. <i>Neuropsychopharmacology</i> , 2022, 47, 1449-1460.	2.8	13
11	Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D ₁ Receptors Localized in the Ventral Tegmental Area as Main Mediators of the Dopaminergic Effects of Ghrelin. <i>Journal of Neuroscience</i> , 2022, 42, 940-953.	1.7	10
12	Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients. <i>European Journal of Internal Medicine</i> , 2022, 101, 76-85.	1.0	6
13	The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder. <i>Biological Psychiatry</i> , 2022, 91, 1008-1018.	0.7	18
14	Brain metabolite alterations related to alcohol use: a meta-analysis of proton magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 3223-3236.	4.1	7
15	Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate. <i>Alcohol and Alcoholism</i> , 2022, 57, 576-580.	0.9	5
16	The future of translational research on alcohol use disorder. <i>Addiction Biology</i> , 2021, 26, e12903.	1.4	22
17	Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use. <i>Addiction Biology</i> , 2021, 26, e12890.	1.4	17
18	Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β -Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders. <i>American Journal on Addictions</i> , 2021, 30, 88-91.	1.3	5

#	ARTICLE	IF	CITATIONS
19	A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021, 26, 545-555.	4.1	21
20	Interventions and Manipulations of Interoception. <i>Trends in Neurosciences</i> , 2021, 44, 52-62.	4.2	92
21	A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers. <i>Clinical Pharmacokinetics</i> , 2021, 60, 471-484.	1.6	7
22	Bots and Misinformation Spread on Social Media: Implications for COVID-19. <i>Journal of Medical Internet Research</i> , 2021, 23, e26933.	2.1	94
23	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	1.0	11
24	Addiction as a brain disease revised: why it still matters, and the need for consilience. <i>Neuropsychopharmacology</i> , 2021, 46, 1715-1723.	2.8	103
25	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1291-1303.	0.9	18
26	The validity of the stateâ€œtrait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. <i>Addiction</i> , 2021, 116, 3055-3068.	1.7	2
27	A neuroimaging investigation into the role of peripheral metabolic biomarkers in the anticipation of reward in alcohol use. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108638.	1.6	4
28	Sensory cue reactivity: Sensitization in alcohol use disorder and obesity. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 124, 326-357.	2.9	10
29	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 296-313.	2.9	17
30	Response to â€œAddiction is a social disease: just as tenable as calling it a brain diseaseâ€œ. <i>Neuropsychopharmacology</i> , 2021, 46, 1713-1714.	2.8	3
31	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A metaâ€œregression analysis to develop an enrichment strategy. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1722-1734.	1.4	12
32	Leptin Gene and Leptin Receptor Gene Polymorphisms in Alcohol Use Disorder: Findings Related to Psychopathology. <i>Frontiers in Psychiatry</i> , 2021, 12, 723059.	1.3	3
33	Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108771.	1.6	8
34	Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. <i>Neuropsychopharmacology</i> , 2021, 46, 2140-2147.	2.8	9
35	The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter. <i>Neuropsychopharmacology</i> , 2021, 46, 2228-2229.	2.8	7
36	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13

#	ARTICLE	IF	CITATIONS
37	Effect of intravenous ghrelin administration, combined with alcohol, on circulating metabolome in heavy drinking individuals with alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2207-2216.	1.4	3
38	A population-based investigation of the association between alcohol intake and serum total ghrelin concentrations among cigarette-smoking, non-alcohol-dependent male individuals. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108835.	1.6	4
39	Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, , 1-9.	1.1	1
40	Cardiovascular Consequences of Excessive Alcohol Drinking via Electrocardiogram. <i>Journal of Addictions Nursing</i> , 2021, 32, 39-45.	0.2	5
41	OUP accepted manuscript. <i>Alcohol and Alcoholism</i> , 2021, , .	0.9	8
42	Blood Biomarkers of Alcohol Use: A Scoping Review. <i>Current Addiction Reports</i> , 2021, 8, 500-508.	1.6	9
43	Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 50, 116465.	1.4	2
44	Thiamine administration to all patients with alcohol use disorder: why not?. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 651-654.	1.1	5
45	An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. <i>Psychopharmacology</i> , 2021, , 1.	1.5	4
46	Gut microbiome and metabolome in a non-human primate model of chronic excessive alcohol drinking. <i>Translational Psychiatry</i> , 2021, 11, 609.	2.4	12
47	The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475.	4.1	90
48	Parsing out the role of dopamine D4 receptor gene (DRD4) on alcohol-related phenotypes: A meta-analysis and systematic review. <i>Addiction Biology</i> , 2020, 25, e12770.	1.4	15
49	A role for the CD38rs3796863 polymorphism in alcohol and monetary reward: evidence from CD38 knockout mice and alcohol self-administration, [11C]-raclopride binding, and functional MRI in humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 167-179.	1.1	3
50	Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. <i>Neuropharmacology</i> , 2020, 170, 107788.	2.0	19
51	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 23-35.	1.4	17
52	New Challenges in Addiction Medicine: COVID-19 Infection in Patients With Alcohol and Substance Use Disorders – The Perfect Storm. <i>American Journal of Psychiatry</i> , 2020, 177, 805-807.	4.0	40
53	Leveraging genetic data to investigate molecular targets and drug repurposing candidates for treating alcohol use disorder and hepatotoxicity. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108155.	1.6	1
54	Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. <i>Frontiers in Neuroscience</i> , 2020, 14, 599646.	1.4	30

#	ARTICLE	IF	CITATIONS
55	Investigating the link between serum concentrations of brain-derived neurotrophic factor and behavioral measures in anxious alcohol-dependent individuals. <i>Alcohol</i> , 2020, 89, 75-83.	0.8	6
56	Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2097-2108.	1.4	11
57	Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 190-202.	2.5	5
58	From "The Red Journal"™, for the Retirement of Editor-in-Chief Philippe De Witte: A Fond and Grateful Farewell. <i>Alcohol and Alcoholism</i> , 2020, 55, 1-2.	0.9	3
59	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71.	2.4	48
60	Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. <i>Brain Research</i> , 2020, 1740, 146851.	1.1	13
61	Understanding plasma treatment effect on human acyl-ghrelin concentrations. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 1585-1589.	0.5	4
62	Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 158-169.	1.4	60
63	Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. <i>Neuropharmacology</i> , 2019, 158, 107711.	2.0	11
64	Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1130-1131, 121820.	1.2	4
65	Peripheral proinflammatory markers are upregulated in abstinent alcohol-dependent patients but are not affected by cognitive bias modification: Preliminary findings. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107553.	1.6	5
66	Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2019, 148, 104447.	3.1	50
67	Advances in the science and treatment of alcohol use disorder. <i>Science Advances</i> , 2019, 5, eaax4043.	4.7	265
68	Using Machine Learning to Classify Individuals With Alcohol Use Disorder Based on Treatment Seeking Status. <i>EClinicalMedicine</i> , 2019, 12, 70-78.	3.2	29
69	Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. <i>Drug Metabolism and Disposition</i> , 2019, 47, 874-882.	1.7	11
70	Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala. <i>PLoS Biology</i> , 2019, 17, e2006421.	2.6	73
71	Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder. <i>Physiology and Behavior</i> , 2019, 204, 49-57.	1.0	80
72	Ghrelin Receptor Influence on Cocaine Reward is Not Directly Dependent on Peripheral Acyl-Ghrelin. <i>Scientific Reports</i> , 2019, 9, 1841.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. Handbook of Experimental Pharmacology, 2019, 258, 443-462.	0.9	19
74	Prospects for pharmacotherapies to treat alcohol use disorder. Current Opinion in Psychiatry, 2019, 32, 255-265.	3.1	25
75	Ghrelin receptor deletion reduces binge-like alcohol drinking in rats. Journal of Neuroendocrinology, 2019, 31, e12663.	1.2	36
76	Reduced plasma ghrelin concentrations are associated with decreased brain reactivity to food cues after laparoscopic sleeve gastrectomy. Psychoneuroendocrinology, 2019, 100, 229-236.	1.3	47
77	Development and initial characterization of a novel ghrelin receptor CRISPR/Cas9 knockout wistar rat model. International Journal of Obesity, 2019, 43, 344-354.	1.6	29
78	Ghrelin: From a Gut Hormone to a Potential Therapeutic Target for Alcohol Addiction. FASEB Journal, 2019, 33, 499.3.	0.2	0
79	The Glucagon-like Peptide-1 (GLP-1) System is Modulated by Acute and Chronic Exposure to Alcohol: Findings from Human Laboratory and Brain Postmortem Studies. FASEB Journal, 2019, 33, .	0.2	0
80	Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology, 2018, 235, 1625-1634.	1.5	51
81	Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. Neuropharmacology, 2018, 137, 230-239.	2.0	8
82	Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans. Journal of Psychopharmacology, 2018, 32, 163-173.	2.0	10
83	Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and Alcoholism, 2018, 53, 268-276.	0.9	24
84	A relationship between the aldosterone-mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans. Molecular Psychiatry, 2018, 23, 1466-1473.	4.1	41
85	Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Molecular Psychiatry, 2018, 23, 115-122.	4.1	201
86	Impulsive Personality Traits Mediate the Relationship Between Adult Attention-Deficit/Hyperactivity Symptoms and Alcohol Dependence Severity. Alcoholism: Clinical and Experimental Research, 2018, 42, 173-183.	1.4	20
87	Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals. Molecular Psychiatry, 2018, 23, 2029-2038.	4.1	82
88	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry, the, 2018, 5, 957-960.	3.7	94
89	Alcohol and Alcoholism: Then, Now and The Future of "The Red Journal"™. Alcohol and Alcoholism, 2018, 53, 637-638.	0.9	3
90	Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders. Frontiers in Psychiatry, 2018, 9, 464.	1.3	22

#	ARTICLE	IF	CITATIONS
91	Identifying and Characterizing Subpopulations of Heavy Alcohol Drinkers Via a Sucrose Preference Test: A Sweet Road to a Better Phenotypic Characterization?. <i>Alcohol and Alcoholism</i> , 2018, 53, 560-569.	0.9	10
92	Stress, Motivation, and the Gut-Brain Axis: A Focus on the Ghrelin System and Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1378-1389.	1.4	47
93	Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 172, 39-49.	1.3	19
94	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	1.9	20
95	Oxytocin receptor mRNA expression in dorsolateral prefrontal cortex in major psychiatric disorders: A human post-mortem study. <i>Psychoneuroendocrinology</i> , 2018, 96, 143-147.	1.3	30
96	Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder: A pilot study. <i>Brain Stimulation</i> , 2018, 11, 1195-1197.	0.7	44
97	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
98	Differences Between Treatment-Seeking and Nontreatment-Seeking Alcohol-Dependent Research Participants: An Exploratory Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 414-420.	1.4	55
99	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. <i>Journal of Psychopharmacology</i> , 2017, 31, 812-818.	2.0	10
100	A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1201-1211.	1.4	20
101	The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1220-1227.	1.4	10
102	The Leu72Met Polymorphism of the Prepro-ghrelin Gene is Associated With Alcohol Consumption and Subjective Responses to Alcohol: Preliminary Findings. <i>Alcohol and Alcoholism</i> , 2017, 52, 425-430.	0.9	26
103	Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. <i>Addiction</i> , 2017, 112, 1808-1820.	1.7	31
104	The Microbiota, the Gut and the Brain in Eating and Alcohol Use Disorders: A <i>MÃ©nage Ã Trois</i> ™?. <i>Alcohol and Alcoholism</i> , 2017, 52, 403-413.	0.9	66
105	Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. <i>Translational Psychiatry</i> , 2017, 7, e1108-e1108.	2.4	45
106	Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence?. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 120-128.	1.3	8
107	Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. <i>Drug and Alcohol Dependence</i> , 2017, 177, 23-28.	1.6	38
108	Rehabilitating the addicted brain with transcranial magnetic stimulation. <i>Nature Reviews Neuroscience</i> , 2017, 18, 685-693.	4.9	184

#	ARTICLE	IF	CITATIONS
109	Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. <i>Data in Brief</i> , 2017, 15, 407-413.	0.5	13
110	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 68-75.	1.6	34
111	Effect of alcohol use disorder on oxytocin peptide and receptor mRNA expression in human brain: A post-mortem case-control study. <i>Psychoneuroendocrinology</i> , 2017, 85, 14-19.	1.3	28
112	A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 78-85.	1.9	29
113	Relationship between craving and plasma leptin concentrations in patients with cocaine addiction. <i>Psychoneuroendocrinology</i> , 2017, 85, 35-41.	1.3	21
114	Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. <i>American Journal of Medicine</i> , 2017, 130, 124-134.	0.6	107
115	The gut in the brain: the effects of bariatric surgery on alcohol consumption. <i>Addiction Biology</i> , 2017, 22, 1540-1553.	1.4	61
116	Alcohol drinking patterns in young people: A survey-based study. <i>Journal of Health Psychology</i> , 2017, 22, 1889-1896.	1.3	22
117	Advances in Pharmacotherapy Development: Human Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2017, 248, 579-613.	0.9	19
118	Commentary on Schmitz <i>et al</i> , (2017): Advancing medication development for addiction—behavioral and neuroimaging outcomes as indirect biomarkers of target engagement. <i>Addiction</i> , 2017, 112, 1869-1870.	1.7	1
119	The Role of the Ghrelin System in Drug Addiction. <i>International Review of Neurobiology</i> , 2017, 136, 89-119.	0.9	74
120	What the alcohol doctor ordered from the neuroscientist. <i>Progress in Brain Research</i> , 2016, 224, 401-418.	0.9	20
121	Role of the 1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. <i>Addiction Biology</i> , 2016, 21, 904-914.	1.4	58
122	The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. <i>Neuropsychopharmacology</i> , 2016, 41, 2818-2829.	2.8	128
123	Modulating Morphine Context-Induced Drug Memory With Deep Brain Stimulation: More Research Questions by Lowering Stimulation Frequencies?. <i>Biological Psychiatry</i> , 2016, 80, 647-649.	0.7	2
124	Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw048.	1.0	11
125	Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. <i>European Neuropsychopharmacology</i> , 2016, 26, 37-44.	0.3	245
126	Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date. <i>CNS Drugs</i> , 2016, 30, 109-123.	2.7	86

#	ARTICLE	IF	CITATIONS
127	Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving. <i>Translational Psychiatry</i> , 2015, 5, e646-e646.	2.4	36
128	Effect of Functionally Significant Deiodinase Single Nucleotide Polymorphisms on Drinking Behavior in Alcohol Dependence: An Exploratory Investigation. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1665-1670.	1.4	5
129	Roux-en-Y Gastric Bypass Alters Brain Activity in Regions that Underlie Reward and Taste Perception. <i>PLoS ONE</i> , 2015, 10, e0125570.	1.1	30
130	Development and validation of an UPLC-MS/MS assay for quantitative analysis of the ghrelin receptor inverse agonist PF-5190457 in human or rat plasma and rat brain. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5603-5613.	1.9	4
131	Investigational therapies for the pharmacological treatment of alcoholism. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 17-30.	1.9	8
132	Identification and Management of Alcohol Withdrawal Syndrome. <i>Drugs</i> , 2015, 75, 353-365.	4.9	127
133	The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. <i>Translational Psychiatry</i> , 2015, 5, e583-e583.	2.4	79
134	Relationship Between the Thyroid Axis and Alcohol Craving. <i>Alcohol and Alcoholism</i> , 2015, 50, 24-29.	0.9	19
135	Management of Alcohol Use Disorder in Patients Requiring Liver Transplant. <i>American Journal of Psychiatry</i> , 2015, 172, 1182-1189.	4.0	20
136	A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. <i>Psychopharmacology</i> , 2015, 232, 233-243.	1.5	36
137	High Ghrelin Levels in Post-treatment Euthyroid Patients with Hashimoto's Thyroiditis: a Case-control Preliminary Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 540-543.	0.6	4
138	Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine?. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1541-1544.	1.0	3
139	Small-Fiber Degeneration in Alcohol-Related Peripheral Neuropathy. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1965-1972.	1.4	36
140	Ondansetron Reduces Naturalistic Drinking in Nontreatment-Seeking Alcohol-Dependent Individuals with the LL 5-HTTLPR Genotype: A Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1567-1574.	1.4	31
141	Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. <i>CNS Drugs</i> , 2014, 28, 343-360.	2.7	65
142	Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date. <i>CNS Drugs</i> , 2014, 28, 107-119.	2.7	15
143	Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. <i>Alcohol and Alcoholism</i> , 2014, 49, 654-660.	0.9	82
144	Pharmacotherapy for alcoholic patients with alcoholic liver disease. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1265-1276.	0.5	42

#	ARTICLE	IF	CITATIONS
145	Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. <i>Alcohol</i> , 2014, 48, 515-522.	0.8	19
146	Intravenous Ghrelin Administration Increases Alcohol Craving in Alcohol-Dependent Heavy Drinkers: A Preliminary Investigation. <i>Biological Psychiatry</i> , 2014, 76, 734-741.	0.7	126
147	Management of Alcohol Dependence in Patients with Liver Disease. <i>CNS Drugs</i> , 2013, 27, 287-299.	2.7	87
148	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.	1.4	156
149	A human laboratory pilot study with baclofen in alcoholic individuals. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 103, 784-791.	1.3	66
150	Alcohol addiction: toward a patient-oriented pharmacological treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2157-2160.	0.9	7
151	Fasting-induced increase in plasma ghrelin is blunted by intravenous alcohol administration: A within-subject placebo-controlled study. <i>Psychoneuroendocrinology</i> , 2013, 38, 3085-3091.	1.3	40
152	Use of Novel Technology-Based Techniques to Improve Alcohol-Related Outcomes in Clinical Trials. <i>Alcohol and Alcoholism</i> , 2013, 48, 712-719.	0.9	28
153	Commentary: Doxazosin for Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 191-193.	1.4	7
154	Baclofen in the treatment of persistent hiccup: a case series. <i>International Journal of Clinical Practice</i> , 2013, 67, 918-921.	0.8	22
155	Roux-en-Y Gastric Bypass Increases Intravenous Ethanol Self-Administration in Dietary Obese Rats. <i>PLoS ONE</i> , 2013, 8, e83741.	1.1	44
156	Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation. <i>Neuropsychopharmacology</i> , 2012, 37, 163-177.	2.8	74
157	The treatment of alcohol and opioid dependence in pregnant women. <i>Current Opinion in Psychiatry</i> , 2012, 25, 559-564.	3.1	35
158	The Relationship of Appetitive, Reproductive and Posterior Pituitary Hormones to Alcoholism and Craving in Humans. <i>Neuropsychology Review</i> , 2012, 22, 211-228.	2.5	33
159	Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. <i>Addictive Behaviors</i> , 2012, 37, 561-564.	1.7	65
160	Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 19.	0.4	95
161	Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. <i>Addiction Biology</i> , 2012, 17, 452-464.	1.4	118
162	Alcohol use disorders in the elderly: A brief overview from epidemiology to treatment options. <i>Experimental Gerontology</i> , 2012, 47, 411-416.	1.2	132

#	ARTICLE	IF	CITATIONS
163	Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review. <i>Current Pharmaceutical Design</i> , 2011, 17, 1323-1332.	0.9	74
164	Role of Feeding-Related Pathways in Alcohol Dependence: A Focus on Sweet Preference, NPY, and Ghrelin. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 194-202.	1.4	66
165	Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. <i>Human Psychopharmacology</i> , 2011, 26, 554-559.	0.7	30
166	Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Alcohol and Alcoholism</i> , 2011, 46, 312-317.	0.9	173
167	Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence. <i>Current Pharmaceutical Design</i> , 2010, 16, 2159-2181.	0.9	31
168	Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research. <i>Current Pharmaceutical Design</i> , 2010, 16, 2074-2075.	0.9	7
169	Role of Trait Anxiety in Persistent Radicular Pain After Surgery for Lumbar Disc Herniation. <i>Neurosurgery</i> , 2010, 67, 265-271.	0.6	31
170	Effectiveness and Safety of Baclofen in the Treatment of Alcohol Dependent Patients. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 33-44.	0.8	104
171	Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients. <i>Current Pharmaceutical Design</i> , 2010, 16, 2113-2117.	0.9	86
172	Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. <i>Drug News and Perspectives</i> , 2010, 23, 157.	1.9	45
173	Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. <i>Current Drug Abuse Reviews</i> , 2009, 2, 135-142.	3.4	66
174	The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 675-686.	1.9	63
175	Understanding and Treating Alcohol Craving and Dependence: Recent Pharmacological and Neuroendocrinological Findings. <i>Alcohol and Alcoholism</i> , 2009, 44, 341-352.	0.9	30
176	Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. , 2009, , 287-310.		5
177	Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. <i>Journal of Psychopharmacology</i> , 2009, 23, 883-890.	2.0	38
178	Is Cortisol Involved in the Alcohol-Related Fat Mass Impairment? A Longitudinal Clinical Study. <i>Alcohol and Alcoholism</i> , 2009, 44, 211-215.	0.9	20
179	A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. <i>Human Psychopharmacology</i> , 2009, 24, 465-472.	0.7	15
180	Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond. <i>Neuropsychology Review</i> , 2009, 19, 115-129.	2.5	173

#	ARTICLE	IF	CITATIONS
181	Hormones and drinking behaviour: New findings on ghrelin, insulin, leptin and volume-regulating hormones. An ESBRA Symposium report. <i>Drug and Alcohol Review</i> , 2009, 28, 160-165.	1.1	25
182	A Within-Group Design of Nontreatment Seeking 5-HTTLPR Genotyped Alcohol-Dependent Subjects Receiving Ondansetron and Sertraline. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 315-323.	1.4	45
183	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1136-1144.	1.4	25
184	Blood Glucose Level, Alcohol Heavy Drinking, and Alcohol Craving During Treatment for Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1539-1544.	1.4	31
185	Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. <i>Alcohol</i> , 2009, 43, 559-563.	0.8	46
186	Increased Serum High-density Lipoprotein-Cholesterol Concentration in Celiac Disease After Gluten-free Diet Treatment Correlates With Body Fat Stores. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 946-949.	1.1	47
187	Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. <i>Alcohol</i> , 2008, 42, 375-381.	0.8	36
188	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. <i>International Journal of Clinical Practice</i> , 2008, 62, 1063-1069.	0.8	120
189	Insulin But Not Insulin Growth Factor-1 Correlates With Craving in Currently Drinking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 450-458.	1.4	43
190	Relationship Between the Hypothalamic-Pituitary-Thyroid Axis and Alcohol Craving in Alcohol-Dependent Patients: A Longitudinal Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 2047-2053.	1.4	38
191	Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. <i>Appetite</i> , 2008, 50, 50-56.	1.8	33
192	New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1106-1117.	2.5	94
193	Acute alcohol intoxication. <i>European Journal of Internal Medicine</i> , 2008, 19, 561-567.	1.0	270
194	Social phobia in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 410-415.	0.6	47
195	Metabolic and Nutritional Features in Adult Celiac Patients. <i>Digestive Diseases</i> , 2008, 26, 128-133.	0.8	32
196	Affective and Psychiatric Disorders in Celiac Disease. <i>Digestive Diseases</i> , 2008, 26, 140-148.	0.8	37
197	Invited Commentary * Serotonin transporter (SERT) brain density and neurobiological cloninger subtypes model: a lesson by human autoradiography studies. <i>Alcohol and Alcoholism</i> , 2008, 43, 148-150.	0.9	17
198	State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. <i>Journal of Neurosurgery</i> , 2008, 108, 281-286.	0.9	108

#	ARTICLE	IF	CITATIONS
199	Superior vena cava thrombosis treated by angioplasty and stenting in a cirrhotic patient with peritoneovenous shunt. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2008, 14, 60-2.	0.3	4
200	Coeliac disease and hearing loss: Preliminary data on a new possible association. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1209-1213.	0.6	23
201	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. <i>Lancet, The</i> , 2007, 370, 1915-1922.	6.3	611
202	Analysis of the T1288R Mutation of the Wilson Disease ATP7B Gene in Four Generations of a Family: Possible Genotype-Phenotype Correlation with Hepatic Onset. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2570-2575.	1.1	11
203	Coenzyme Q 10 and Cardiovascular Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss Patients. <i>Otology and Neurotology</i> , 2007, 28, 878-883.	0.7	28
204	Primary renal angiosarcoma: A rare malignancy. A case report and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 307-312.	0.8	48
205	Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam. <i>American Journal of Medicine</i> , 2006, 119, 276.e13-276.e18.	0.6	173
206	Cutaneous manifestations in celiac disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 843.	1.4	77
207	Relationship Between Ghrelin Levels, Alcohol Craving, and Nutritional Status in Current Alcoholic Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2006, 30, 1933-1937.	1.4	154
208	Baclofen: a new drug for the treatment of alcohol dependence. <i>International Journal of Clinical Practice</i> , 2006, 60, 1003-1008.	0.8	63
209	A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia. <i>Digestive Diseases and Sciences</i> , 2006, 51, 34-38.	1.1	8
210	Marked Decrease of Serum Ca 125 Levels After Denver Shunt Placement in a Patient With Cirrhosis and Refractory Ascites. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1644-1646.	1.1	2
211	Tolerance to baclofen's sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence. <i>Psychopharmacology</i> , 2005, 178, 351-352.	1.5	7
212	How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review. <i>Neuropsychobiology</i> , 2005, 51, 59-66.	0.9	117
213	Wilson's Disease: Clinical, Genetic and Pharmacological Findings. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 7-14.	1.0	25
214	Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. <i>Addictive Behaviors</i> , 2005, 30, 1209-1224.	1.7	147
215	Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 777-782.	1.9	90
216	Rapid Regression of Psoriasis in a Coeliac Patient after Gluten-Free Diet. <i>Digestion</i> , 2003, 68, 9-12.	1.2	57

#	ARTICLE	IF	CITATIONS
217	Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report. <i>Clinical Neuropharmacology</i> , 2003, 26, 258-262.	0.2	56
218	Pharmacological approaches to the management of alcohol addiction. <i>European Review for Medical and Pharmacological Sciences</i> , 2002, 6, 89-97.	0.5	13